Targeting tumor cell motility to prevent metastasis

Advanced Drug Delivery Reviews

Volumn 63, Issue 8, 2011, Pages 568-581

  Palmer, Trenis D ^a   Ashby, William J ^a   Lewis, John D ^b   Zijlstra, Andries ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Adhesion; Intravasation; Invasion; Metastasis; Migration; Motility; Therapy; Tumor

Indexed keywords

INTRAVASATION; INVASION; METASTASIS; MIGRATION; MOTILITY; THERAPY;

ADHESION; CELL ADHESION; CELLS; DISEASES; GENES; PATHOLOGY; TUMORS;

SCAFFOLDS (BIOLOGY);

A 6; ADH 1; AMG 208; ANTINEOPLASTIC AGENT; ATN 658; BEVACIZUMAB; BOSUTINIB; CILENGITIDE; CTCE 9908; CURCUMIN; DASATINIB; EMODIN; ENDOSTATIN; ETARACIZUMAB; EXHERIN; FASUDIL; FRESOLIMUMAB; IGN 101; INFLIXIMAB; LMD 121974; MESUPRON; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; ONARTUZUMAB; PI 88; REBIMASTAT; SARACATINIB; TEMPOSTATIN; TIGAPOTIDE; TRABEDERSEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLOCIXIMAB; WX 671;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL ADHESION; CELL COMMUNICATION; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELLULAR DISTRIBUTION; DNA INTEGRATION; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TARGET CELL;

ANIMALS; CELL ADHESION; CELL COMMUNICATION; CELL MOVEMENT; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 79959918753     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.04.008     Document Type: Review

References (185)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(5):277. (PMID: 17982957816353055660related:rOOOLttMkPkJ).
2. Schwartz M., Yap A. Cell-to-cell contact and extracellular matrix. Curr. Opin. Cell Biol. 2006, 18(5):461-462. (PMID). 10.1016/j.ceb.2006.08.013.
3. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302(5651):1704-1709. (PMID: 14657486). 10.1126/science.1092053.
4. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr. Opin. Cell Biol. 2004, 16(1):14-23. (PMID: 15037300). 10.1016/j.ceb.2003.11.001.
5. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3(5):362-374. (PMID: 12724734). 10.1038/nrc1075.
6. Rørth P. Collective guidance of collective cell migration. Trends Cell Biol. 2007, 17(12):575-579. (PMID: 17996447). 10.1016/j.tcb.2007.09.007.
7. Bockhorn M., Jain R.K., Munn L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncol. 2007, 8(5):444-448. (PMID: 17466902). 10.1016/S1470-2045(07)70140-7.
8. Sugino T., Kusakabe T., Hoshi N., Yamaguchi T., Kawaguchi T., Goodison S., Sekimata M., Homma Y., Suzuki T. An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model. Am. J. Pathol. 2002, 160(6):1973-1980.
9. Nguyen D.X., Bos P.D., Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9(4):274-284. (PMID: 19308067). 10.1038/nrc2622.
10. Ward P.M., Weiss L. Metachronous seeding of lymph node metastases in rats bearing the MT-100-TC mammary carcinoma: the effect of elective lymph node dissection. Breast Cancer Res. Treat. 1989, 14(3):315-320. (PMID: 2611404).
11. Sleeman J., Schmid A., Thiele W. Tumor lymphatics. Semin. Cancer Biol. 2009, 19(5):285-297. (PMID: 19482087). 10.1016/j.semcancer.2009.05.005.
12. Weaver D.L., Ashikaga T., Krag D.N., Skelly J.M., Anderson S.J., Harlow S.P., Julian T.B., Mamounas E.P., Wolmark N. Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. N. Engl. J. Med. 2011, (PMID: 21247310). 10.1056/NEJMoa1008108.
13. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8(5):341-352. (PMID: 17440531). 10.1038/nrg2101.
14. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3(6):453-458. (PMID: 12778135). 10.1038/nrc1098.
15. Hart I.R., Fidler I.J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 1980, 40(7):2281-2287. (PMID: 7388794).
16. Kim M.-Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H.-F., Norton L., Massagué J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139(7):1315-1326. (PMID: 20064377). 10.1016/j.cell.2009.11.025.
17. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9(4):302-312. (PMID: 19308069). 10.1038/nrc2627.
18. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447(7143):433-440. (PMID: 17522677). 10.1038/nature05919.
19. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119(6):1420-1428. (PMID: 19487818). 10.1172/JCI39104.
20. Nguyen D.X., Massagué J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8(5):341-352. (PMID: 17440531). 10.1038/nrg2101.
21. Paget S. The distribution of secondary growths in cancer of the breast. Lancet March 1889, 23:571-573. (PMID).
22. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 2000, 19(3-4):I-XI. (193-383, PMID: 11394186).
23. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2(8):584-593. (PMID: 12154351). 10.1038/nrc867.
24. Allen M., Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223(2):162-176. (PMID: 21125673). 10.1002/path.2803.
25. Francia G., Emmenegger U., Kerbel R. Tumor-Associated Fibroblasts as "Trojan Horse" Mediators of Resistance to Anti-VEGF Therapy. Cancer Cell 2009, 15(1):3-5. (PMID). 10.1016/j.ccr.2008.12.011.
26. Franco O.E., Shaw A.K., Strand D.W., Hayward S.W. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 2010, 21(1):33-39. (PMID: 19896548). 10.1016/j.semcdb.2009.10.010.
27. Peinado H., Lavothskin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, (PMID: 21251983). 10.1016/j.semcancer.2011.01.002.
28. Ewing J. Neoplastic Diseases: A Textbook on Tumors 1940, fourth ed., Philadelphia and London, 1919.
29. Weiss L. Dynamic aspects of cancer cell populations in metastasis. Am. J. Pathol. 1979, 97(3):601-608. (PMID: 389067).
30. Tarin D., Vass A.C., Kettlewell M.G., Price J.E. Absence of metastatic sequelae during long-term treatment of malignant ascites by peritoneo-venous shunting. A clinico-pathological report. Invasion Metastasis 1984, 4(1):1-12. (PMID: 6735637).
31. Orr J.A., Hamilton P.W. Histone acetylation and chromatin pattern in cancer. A review. Anal. Quant. Cytol. Histol. 2007, 29(1):17-31.
32. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17(3):330-339. (PMID: 21386836). 10.1038/nm.2305.
33. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124(2):263-266. (PMID: 16439202). 10.1016/j.cell.2006.01.007.
34. Fingleton B. Molecular targets in metastasis: lessons from genomic approaches. Cancer Genomics Proteomics 2007, 4(3):211-221. (PMID: 17878524).
35. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26(2):281-290. (PMID: 17603752). 10.1007/s10555-007-9066-y.
36. Sullivan R., Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007, 26(2):319-331. (PMID: 17458507). 10.1007/s10555-007-9062-2.
37. Erler J.T., Weaver V.M. Three-dimensional context regulation of metastasis. Clin. Exp. Metastasis 2009, 26(1):35-49. (PMID: 18814043). 10.1007/s10585-008-9209-8.
38. Kumar S., Weaver V. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, (PMID: 19153673). 10.1007/s10555-008-9173-4.
39. Ruppender N.S., Merkel A.R., Martin T.J., Mundy G.R., Sterling J.A., Guelcher S.A. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One 2010, 5(11):e15451. (PMID: 21085597). 10.1371/journal.pone.0015451.
40. Sethi S., Macoska J., Chen W., Sarkar F.H. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res. 2010, 3(1):90-99. (PMID: 21139809).
41. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., Guise T.A., Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549. (PMID: 12842083).
42. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massagué J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524. (PMID: 16049480). 10.1038/nature03799.
43. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163):682. (PMID). 10.1038/nature06174.
44. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10(1):9-22. (PMID: 20029421). 10.1038/nrc2748.
45. Craig S.E.L., Brady-Kalnay S.M. Cancer cells cut homophilic cell adhesion molecules and run. Cancer Res. 2011, 71(2):303-309. (PMID: 21084269). 10.1158/0008-5472.
46. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4(2):118-132. (PMID: 14964308).
47. Liu S., Calderwood D.A., Ginsberg M.H. Integrin cytoplasmic domain-binding proteins. J. Cell Sci. 2000, 113(Pt 20):3563-3571. (PMID: 11017872).
48. Calderwood D.A., Zent R., Grant R., Rees D.J., Hynes R.O., Ginsberg M.H. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J. Biol. Chem. 1999, 274(40):28071-28074. (PMID: 10497155).
49. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25(1):9-34. (PMID: 16680569). 10.1007/s10555-006-7886-9.
50. López-Otín C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7(10):800-808. (PMID: 17851543). 10.1038/nrc2228.
51. Wolf K., Wu Y.I., Liu Y., Geiger J., Tam E., Overall C., Stack M.S., Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9(8):893-904. (PMID: 17618273). 10.1038/ncb1616.
52. Clark E.A., Golub T.R., Lander E.S., Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000, 406(6795):532-535. (PMID: 10952316). 10.1038/35020106.
53. Lämmermann T., Bader B.L., Monkley S.J., Worbs T., Wedlich-Söldner R., Hirsch K., Keller M., Förster R., Critchley D.R., Fässler R., Sixt M. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008, 453(7191):51-55. (PMID: 18451854). 10.1038/nature06887.
54. Parsons J.T., Horwitz A.R., Schwartz M.A. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat. Rev. Mol. Cell Biol. 2010, 11(9):633-643. (PMID: 20729930). 10.1038/nrm2957.
55. Aleshin A., Finn R.S. SRC: a century of science brought to the clinic. Neoplasia 2010, 12(8):599-607. (PMID: 20689754).
56. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4(6):470-480. (PMID: 15170449). 10.1038/nrc1366.
57. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13:513-609. (PMID: 9442882). 10.1146/annurev.cellbio.13.1.513.
58. Kikyo M., Matozaki T., Kodama A., Kawabe H., Nakanishi H., Takai Y. Cell-cell adhesion-mediated tyrosine phosphorylation of nectin-2delta, an immunoglobulin-like cell adhesion molecule at adherens junctions. Oncogene 2000, 19(35):4022-4028. (PMID: 10962558). 10.1038/sj.onc.1203744.
59. Abram C.L., Courtneidge S.A. Src family tyrosine kinases and growth factor signaling. Exp. Cell Res. 2000, 254(1):1-13. (PMID: 10623460). 10.1006/excr.1999.4732.
60. Gallo R., Provenzano C., Carbone R., Di Fiore P.P., Castellani L., Falcone G., Alemà S. Regulation of the tyrosine kinase substrate Eps8 expression by growth factors, v-Src and terminal differentiation. Oncogene 1997, 15(16):1929-1936. (PMID: 9365239). 10.1038/sj.onc.1201344.
61. Takenawa T., Miki H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J. Cell Sci. 2001, 114(10):1801. (PMID).
62. Sarmiento C., Wang W., Dovas A., Yamaguchi H., Sidani M., El-Sibai M., DesMarais V., Holman H.A., Kitchen S., Backer J.M., Alberts A., Condeelis J. WASP family members and formin proteins coordinate regulation of cell protrusions in carcinoma cells. J. Cell Biol. 2008, 180(6):1245-1260. (PMID: 18362183). 10.1083/jcb.200708123.
63. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7):927-939. (PMID: 15210113). 10.1016/j.cell.2004.06.006.
64. Han H.-J., Russo J., Kohwi Y., Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452(7184):187-193. (PMID: 18337816). 10.1038/nature06781.
65. Nicoloso M.S., Spizzo R., Shimizu M., Rossi S., Calin G.A. MicroRNAs - the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9(4):293-302. (PMID: 19262572). 10.1038/nrc2619.
66. Varambally S., Cao Q., Mani R.-S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., Brenner J.C., Yu J., Kim J.H., Han B., Tan P., Kumar-Sinha C., Lonigro R.J., Palanisamy N., Maher C.A., Chinnaiyan A.M. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322(5908):1695-1699. (PMID: 19008416). 10.1126/science.1165395.
67. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, (PMID: 21240262). 10.1038/nm.2284.
68. Mueller L., von Seggern L., Schumacher J., Goumas F., Wilms C., Braun F., Broering D.C. TNF-alpha similarly induces IL-6 and MCP-1 in fibroblasts from colorectal liver metastases and normal liver fibroblasts. Biochem. Biophys. Res. Commun. 2010, 397(3):586-591. (PMID: 20617559).
69. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9(12):1392-1400. (PMID: 18037882). 10.1038/ncb1658.
70. Gao D., Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol. Med. 2009, 15(8):333-343. (PMID: 19665928). 10.1016/j.molmed.2009.06.006.
71. Bergfeld S.A., DeClerck Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010, 29(2):249-261. (PMID: 20411303). 10.1007/s10555-010-9222-7.
72. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563. (PMID: 17914389). 10.1038/nature06188.
73. van der Gun B.T.F., Melchers L.J., Ruiters M.H.J., de Leij L.F.M.H., McLaughlin P.M.J., Rots M.G. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31(11):1913-1921. (PMID: 20837599). 10.1093/carcin/bgq187.
74. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 2010, 10(3):165-180. (PMID: 20179713). 10.1038/nrc2806.
75. Hansen A.G., Swart G.W., Zijlstra A. ALCAM. UCSD-Nature Molecule Pages 2011, (PMID: doi:10.1038).
76. Siesser P.F., Maness P.F. L1 cell adhesion molecules as regulators of tumor cell invasiveness. Cell Adh. Migr. 2009, 3(3):275-277. (PMID: 19483471).
77. Ramirez N.E., Zhang Z., Madamanchi A., Boyd K.L., O'Rear L.D., Nashabi A., Li Z., Dupont W.D., Zijlstra A., Zutter M.M. The αβ integrin is a metastasis suppressor in mouse models and human cancer. J. Clin. Invest. 2011, 121(1):226-237. (PMID: 21135504). 10.1172/JCI42328.
78. Schneider J.G., Amend S.R., Weilbaecher K.N. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 2011, 48(1):54-65. (PMID: 20850578). 10.1016/j.bone.2010.09.016.
79. Manon-Jensen T., Itoh Y., Couchman J.R. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 2010, 277(19):3876-3889. (PMID: 20840585). 10.1111/j.1742-4658.2010.07798.x.
80. Klingbeil P., Marhaba R., Jung T., Kirmse R., Ludwig T., Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol. Cancer Res. 2009, 7(2):168-179. (PMID: 19208744). 10.1158/1541-7786.MCR-08-0207.
81. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278(1):16-27. (PMID: 21087457). 10.1111/j.1742-4658.2010.07919.x.
82. Guess C.M., Quaranta V. Defining the role of laminin-332 in carcinoma. Matrix Biol. 2009, 28(8):445-455. (PMID: 19686849). 10.1016/j.matbio.2009.07.008.
83. Guttery D.S., Shaw J.A., Lloyd K., Pringle J.H., Walker R.A. Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev. 2010, 29(4):595-606. (PMID: 20814719). 10.1007/s10555-010-9249-9.
84. Hancox R.A., Allen M.D., Holliday D.L., Edwards D.R., Pennington C.J., Guttery D.S., Shaw J.A., Walker R.A., Pringle J.H., Jones J.L. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res. 2009, 11(2):R24. (PMID: 19405959). 10.1186/bcr2251.
85. Kaczmarek J., Castellani P., Nicolo G., Spina B., Allemanni G., Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 1994, 59(1):11-16. (PMID: 7927891).
86. Nerenberg R., Kawagoshi Y., Rittmann B.E. Microbial ecology of a perchlorate-reducing, hydrogen-based membrane biofilm reactor. Water Res. 2008, 42(4-5):1151-1159. (PMID: 17915282). 10.1016/j.watres.2007.08.033.
87. Wildenberg G.A., Dohn M.R., Carnahan R.H., Davis M.A., Lobdell N.A., Settleman J., Reynolds A.B. p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell 2006, 127(5):1027-1039. (PMID: 17129772). 10.1016/j.cell.2006.09.046.
88. Reynolds A.B. p120-catenin: past and present. Biochim. Biophys. Acta 2006, 1773(1):2-7. (PMID: 17175391). 10.1016/j.bbamcr.2006.09.019.
89. Daniel J.M., Reynolds A.B. The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol. Cell. Biol. 1999, 19(5):3614-3623. (PMID: 10207085).
90. Anastasiadis P.Z. p120-ctn: a nexus for contextual signaling via Rho GTPases. Biochim. Biophys. Acta 2007, 1773(1):34-46. (PMID: 17028013). 10.1016/j.bbamcr.2006.08.040.
91. Cabodi S., del Pilar Camacho-Leal M., Di Stefano P., Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat. Rev. Cancer 2010, 10(12):858-870. (PMID: 21102636). 10.1038/nrc2967.
92. Weiss L. The Cell Periphery, Metastasis and other Contact Phenomena 1967, North-Holland Pub. Co., Amsterdam.
93. Burridge K., Fath K., Kelly T., Nuckolls G., Turner C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu. Rev. Cell Biol. 1988, 4:487-525. (PMID: 3058164). 10.1146/annurev.cb.04.110188.002415.
94. Dubash A.D., Menold M.M., Samson T., Boulter E., García-Mata R., Doughman R., Burridge K. Chapter 1. Focal adhesions: new angles on an old structure. Int. Rev. Cell Mol. Biol. 2009, 277:1-65. (PMID: 19766966). 10.1016/S1937-6448(09)77001-7.
95. Förster C. Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 2008, 130(1):55-70. (PMID: 18415116). 10.1007/s00418-008-0424-9.
96. Patra S.K. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim. Biophys. Acta 2008, 1785(2):182-206. (PMID: 18166162). 10.1016/j.bbcan.2007.11.002.
97. Hemler M.E. Targeting of tetraspanin proteins - potential benefits and strategies. Nat. Rev. Drug Discov. 2008, 7(9):747-758. (PMID: 18758472). 10.1038/nrd2659.
98. Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 2009, 9(1):40-55. (PMID: 19078974). 10.1038/nrc2543.
99. Zijlstra A. Tetraspanins in Cancer. Cell-Extracellular Matrix Interactions in Cancer 2010, (PMID: related:Z22uFWwOFp8J).
100. Lafleur M., Xu D., Hemler M. Tetraspanin Proteins Regulate Membrane Type-1 Matrix Metalloproteinase (MT1-MMP)-dependent Pericellular Proteolysis. Mol. Biol. Cell 2009, (PMID: 19211836). 10.1091/mbc.E08-11-1149.
101. Palmer D.T., Zijlstra A. CD151. UCSD-Nature Molecule Pages 2011, (PMID: doi:10.1038).
102. Liu W.M., Zhang X.A. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 2006, 240(2):183-194. (PMID: 16260083). 10.1016/j.canlet.2005.08.018.
103. Zijlstra A., Lewis J., Degryse B., Stuhlmann H., Quigley J.P. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008, 13(3):221-234. (PMID: 18328426). 10.1016/j.ccr.2008.01.031.
104. Mackay C.R. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat. Immunol. 2008, 9(9):988-998. (PMID: 18711436). 10.1038/ni.f.210.
105. Wu Y., Deng J., Rychahou P.G., Qiu S., Evers B.M., Zhou B.P. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15(5):416-428. (PMID: 19411070; doi:S1535-6108(09)00085-3).
106. Casas E., Kim J., Bendesky A., Ohno-Machado L., Wolfe C.J., Yang J. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 2011, 71(1):245-254. (PMID: 21199805; doi:71/1/245).
107. Bhatt A.S., Erdjument-Bromage H., Tempst P., Craik C.S., Moasser M.M. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005, 24(34):5333-5343. (PMID: 16007225; doi:1208582).
108. Vogelmann R., Nguyen-Tat M.D., Giehl K., Adler G., Wedlich D., Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J. Cell Sci. 2005, 118(Pt 20):4901-4912. (PMID: 16219695; doi:118/20/4901).
109. Zavadil J., Böttinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24(37):5764-5774. (PMID: 16123809). 10.1038/sj.onc.1208927.
110. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6(7):506-520. (PMID: 16794634). 10.1038/nrc1926.
111. Edwards J.R., Nyman J.S., Lwin S.T., Moore M.M., Esparza J., O'Quinn E.C., Hart A.J., Biswas S., Patil C.A., Lonning S., Mahadevan-Jansen A., Mundy G.R. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J. Bone Miner. Res. 2010, 25(11):2419-2426. (PMID: 20499365). 10.1002/jbmr.139.
112. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23(11):2445-2459. (PMID: 15753456). 10.1200/JCO.2005.11.890.
113. Bublil E.M., Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 2007, 19(2):124-134. (PMID: 17314037). 10.1016/j.ceb.2007.02.008.
114. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5(5):341-354. (PMID: 15864276). 10.1038/nrc1609.
115. Sangaletti S., Tripodo C., Ratti C., Piconese S., Porcasi R., Salcedo R., Trinchieri G., Colombo M.P., Chiodoni C. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res. 2010, 70(20):7764-7775. (PMID: 20924115; doi:0008-5472.CAN-10-0471).
116. Bouwmeester T., Bauch A., Ruffner H., Angrand P.-O., Bergamini G., Croughton K., Cruciat C., Eberhard D., Gagneur J., Ghidelli S., Hopf C., Huhse B., Mangano R., Michon A.-M., Schirle M., Schlegl J., Schwab M., Stein M.A., Bauer A., Casari G., Drewes G., Gavin A.-C., Jackson D.B., Joberty G., Neubauer G., Rick J., Kuster B., Superti-Furga G. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat. Cell Biol. 2004, 6(2):97-105. (PMID: 14743216). 10.1038/ncb1086.
117. Tanaka H., Kono E., Tran C.P., Miyazaki H., Yamashiro J., Shimomura T., Fazli L., Wada R., Huang J., Vessella R.L., An J., Horvath S., Gleave M., Rettig M.B., Wainberg Z.A., Reiter R.E. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 2010, 16(12):1414-1420. (PMID: 21057494). 10.1038/nm.2236.
118. Tomita K., van Bokhoven A., van Leenders G.J., Ruijter E.T., Jansen C.F., Bussemakers M.J., Schalken J.A. Cadherin switching in human prostate cancer progression. Cancer Res. 2000, 60(13):3650-3654. (PMID: 10910081).
119. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119(6):1420-1428. (PMID: 19487818). 10.1172/JCI39104.
120. Osta W.A., Chen Y., Mikhitarian K., Mitas M., Salem M., Hannun Y.A., Cole D.J., Gillanders W.E. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004, 64(16):5818-5824. (PMID: 15313925). 10.1158/0008-5472.
121. van der Gun B.T., Melchers L.J., Ruiters M.H., de Leij L.F., McLaughlin P.M., Rots M.G. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31(11):1913-1921. (PMID: 20837599; doi:bgq187).
122. Singh A.B., Sharma A., Dhawan P. Claudin family of proteins and cancer: an overview. J. Oncol. 2010, 2010. (541957, PMID: 20671913). 10.1155/2010/541957.
123. Tabaries S., Dong Z., Annis M.G., Omeroglu A., Pepin F., Ouellet V., Russo C., Hassanain M., Metrakos P., Diaz Z., Basik M., Bertos N., Park M., Guettier C., Adam R., Hallett M., Siegel P.M. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2010, (PMID: 21076473; doi:onc2010518).
124. Oku N., Sasabe E., Ueta E., Yamamoto T., Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 2006, 66(10):5251-5257. (PMID: 16707450; doi:66/10/5251).
125. Carroll R.E., Benya R.V., Turgeon D.K., Vareed S., Neuman M., Rodriguez L., Kakarala M., Carpenter P.M., McLaren C., Meyskens F.L., Brenner D.E. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. (Phila.) 2011, 4(3):354-364. (PMID: 21372035). 10.1158/1940-6207.CAPR-10-0098.
126. Fury M.G., Baxi S., Shen R., Kelly K.W., Lipson B.L., Carlson D., Stambuk H., Haque S., Pfister D.G. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011, 31(1):249-253. (PMID: 21273606).
127. Boschelli F., Arndt K., Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur. J. Cancer 2010, 46(10):1781-1789. (PMID: 20399641). 10.1016/j.ejca.2010.02.032.
128. Johnson F.M., Bekele B.N., Feng L., Wistuba I., Tang X.M., Tran H.T., Erasmus J.J., Hwang L.-L., Takebe N., Blumenschein G.R., Lippman S.M., Stewart D.J. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28(30):4609-4615. (PMID: 20855820). 10.1200/JCO.2010.30.5474.
129. Fujita H., Fukumoto Y., Saji K., Sugimura K., Demachi J., Nawata J., Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010, 25(2):144-149. (PMID: 20339976). 10.1007/s00380-009-1176-8.
130. Srinivas G., Babykutty S., Sathiadevan P.P., Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med. Res. Rev. 2007, 27(5):591-608. (PMID: 17019678). 10.1002/med.20095.
131. Kavsak P.A., Henderson M., Moretto P., Hirte H., Evans K., Wong D., Korz W., Hotte S.J. Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent. Clin. Biochem. 2009, 42(10-11):1162-1165. (PMID: 19389390). 10.1016/j.clinbiochem.2009.04.008.
132. Jin H., Yang R., Zheng Z., Romero M., Ross J., Bou-Reslan H., Carano R.A.D., Kasman I., Mai E., Young J., Zha J., Zhang Z., Ross S., Schwall R., Colbern G., Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008, 68(11):4360-4368. (PMID: 18519697). 10.1158/0008-5472.CAN-07-5960.
133. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., Balasubramaniam A., Nair S., Oliushine V., Parfenov V., Poverennova I., Zaaroor M., Jachimczak P., Ludwig S., Schmaus S., Heinrichs H., Schlingensiepen K.-H., Group T.G.S. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011, 13(1):132-142. (PMID: 20980335). 10.1093/neuonc/noq142.
134. Jatoi A., Ritter H.L., Dueck A., Nguyen P.L., Nikcevich D.A., Luyun R.F., Mattar B.I., Loprinzi C.L. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010, 68(2):234-239. (PMID: 19665818). 10.1016/j.lungcan.2009.06.020.
135. Perotti A., Sessa C., Mancuso A., Noberasco C., Cresta S., Locatelli A., Carcangiu M.L., Passera K., Braghetti A., Scaramuzza D., Zanaboni F., Fasolo A., Capri G., Miani M., Peters W.P., Gianni L. Clinical and pharmacological phase I evaluation of exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann. Oncol. 2009, 20(4):741-745. (PMID: 19190075). 10.1093/annonc/mdn695.
136. Alva A., Slovin S., Daignault S., Carducci M., Dipaola R., Pienta K., Agus D., Cooney K., Chen A., Smith D.C., Hussain M. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest. New Drugs 2010, (PMID: 21049281). 10.1007/s10637-010-9573-5.
137. Bell-McGuinn K.M., Matthews C.M., Ho S.N., Barve M., Gilbert L., Penson R.T., Lengyel E., Palaparthy R., Gilder K., Vassos A., McAuliffe W., Weymer S., Barton J., Schilder R.J. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol. Oncol. 2011, (PMID: 21276608). 10.1016/j.ygyno.2010.12.362.
138. Hersey P., Sosman J., O'Day S., Richards J., Bedikian A., Gonzalez R., Sharfman W., Weber R., Logan T., Buzoianu M., Hammershaimb L., Kirkwood J.M., Group E.M.S. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116(6):1526-1534. (PMID: 20108344). 10.1002/cncr.24821.
139. Cianfrocca M.E., Kimmel K.A., Gallo J., Cardoso T., Brown M.M., Hudes G., Lewis N., Weiner L., Lam G.N., Brown S.C., Shaw D.E., Mazar A.P., Cohen R.B. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 2006, 94(11):1621-1626. (PMID: 16705310). 10.1038/sj.bjc.6603171.
140. Lara P.N., Stadler W.M., Longmate J., Quinn D.I., Wexler J., Van Loan M., Twardowski P., Gumerlock P.H., Vogelzang N.J., Vokes E.E., Lenz H.J., Doroshow J.H., Gandara D.R. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin. Cancer Res. 2006, 12(5):1556-1563. (PMID: 16533781). 10.1158/1078-0432.CCR-05-2074.
141. Zhao X., Mei K., Cai X., Chen J., Yu J., Zhou C., Li Q. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest. New Drugs 2011, (PMID: 21225314). 10.1007/s10637-011-9631-7.
142. Hawkins R.E., Daigneault L., Cowan R., Griffiths R., Panchal C., Armstrong A., Fenemore J., Irvine A., Sereda K., Dulude H. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin. Prostate Cancer 2005, 4(2):91-99. (PMID: 16197609).
143. Meyer J.E., Brocks C., Graefe H., Mala C., Thäns N., Bürgle M., Rempel A., Rotter N., Wollenberg B., Lang S. The oral serine protease inhibitor WX-671 - first experience in patients with advanced head and neck carcinoma. Breast Care (Basel) 2008, 3(s2):20-24. (PMID: 20824010). 10.1159/000151736.
144. de Jonge M.J.A., Dumez H., Verweij J., Yarkoni S., Snyder D., Lacombe D., Marréaud S., Yamaguchi T., Punt C.J.A., van Oosterom A. (NDDG) ENDDG. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur. J. Cancer 2006, 42(12):1768-1774. (PMID: 16815702). 10.1016/j.ejca.2005.12.027.
145. Khasraw M., Pavlakis N., McCowatt S., Underhill C., Begbie S., de Souza P., Boyce A., Parnis F., Lim V., Harvie R., Marx G. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann. Oncol. 2010, 21(6):1302-1307. (PMID: 19917571). 10.1093/annonc/mdp524.
146. Hassan S., Buchanan M., Jahan K., Aguilar-Mahecha A., Gaboury L., Muller W.J., Alsawafi Y., Mourskaia A.A., Siegel P.M., Salvucci O., Basik M. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Cancer 2010, (PMID: 20830712). 10.1002/ijc.25665.
147. Huang E.H., Singh B., Cristofanilli M., Gelovani J., Wei C., Vincent L., Cook K.R., Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res. 2009, 155(2):231-236. (PMID: 19482312). 10.1016/j.jss.2008.06.044.
148. Sloan E.K., Pouliot N., Stanley K.L., Chia J., Moseley J.M., Hards D.K., Anderson R.L. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006, 8(2):R20. (PMID: 16608535). 10.1186/bcr1398.
149. Ding K., Lopez-Burks M., Sanchez-Duran J.A., Korc M., Lander A.D. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 2005, 171(4):729-738. (PMID: 16286510; doi:jcb.200508010).
150. Juuti A., Nordling S., Lundin J., Louhimo J., Haglund C. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005, 68(2-3):97-106. (PMID: 15886501; doi:OCL20050682_3097).
151. Beauvais D.M., Burbach B.J., Rapraeger A.C. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J. Cell Biol. 2004, 167(1):171-181. (PMID: 15479743; doi:jcb.200404171).
152. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 2001, 153(5):893-904. (PMID: 11381077).
153. Zhang Y., Thant A.A., Machida K., Ichigotani Y., Naito Y., Hiraiwa Y., Senga T., Sohara Y., Matsuda S., Hamaguchi M. Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res. 2002, 62(14):3962-3965. (PMID: 12124327).
154. Calderwood D.A., Fujioka Y., de Pereda J.M., Garcia-Alvarez B., Nakamoto T., Margolis B., McGlade C.J., Liddington R.C., Ginsberg M.H. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(5):2272-2277. (PMID: 12606711). 10.1073/pnas.262791999.
155. Cantor J.M., Ginsberg M.H., Rose D.M. Integrin-associated proteins as potential therapeutic targets. Immunol. Rev. 2008, 223:236-251. (PMID: 18613840; doi:IMR640).
156. Arnaout M.A., Goodman S.L., Xiong J.P. Structure and mechanics of integrin-based cell adhesion. Curr. Opin. Cell Biol. 2007, 19(5):495-507. (PMID: 17928215; doi:S0955-0674(07)00119-6).
157. Carnahan R.H., Rokas A., Gaucher E.A., Reynolds A.B. The molecular evolution of the p120-catenin subfamily and its functional associations. PLoS One 2010, 5(12):e15747. (PMID: 21209830). 10.1371/journal.pone.0015747.
158. Robert G., Gaggioli C., Bailet O., Chavey C., Abbe P., Aberdam E., Sabatié E., Cano A., Garcia de Herreros A., Ballotti R., Tartare-Deckert S. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 2006, 66(15):7516-7523. (PMID: 16885349). 10.1158/0008-5472.CAN-05-3189.
159. Arnold S.A., Brekken R.A. SPARC: a matricellular regulator of tumorigenesis. J. Cell Commun. Signal. 2009, 3(3-4):255-273. (PMID: 19809893). 10.1007/s12079-009-0072-4.
160. Cabodi S., Tinnirello A., Bisaro B., Tornillo G., del Pilar Camacho-Leal M., Forni G., Cojoca R., Iezzi M., Amici A., Montani M., Eva A., Di Stefano P., Muthuswamy S.K., Tarone G., Turco E., Defilippi P. p130Cas is an essential transducer element in ErbB2 transformation. FASEB J. 2010, 24(10):3796-3808. (PMID: 20505116). 10.1096/fj.10-157347.
161. Tikhmyanova N., Little J.L., Golemis E.A. CAS proteins in normal and pathological cell growth control. Cell. Mol. Life Sci. 2010, 67(7):1025-1048. (PMID: 19937461). 10.1007/s00018-009-0213-1.
162. Kinley A.W., Weed S.A., Weaver A.M., Karginov A.V., Bissonette E., Cooper J.A., Parsons J.T. Cortactin interacts with WIP in regulating Arp2/3 activation and membrane protrusion. Curr. Biol. 2003, 13(5):384-393. (PMID: 12620186; [pii]; doi:S0960982203001076).
163. Clark E.S., Weaver A.M. A new role for cortactin in invadopodia: regulation of protease secretion. Eur. J. Cell Biol. 2008, 87(8-9):581-590. (PMID: 18342393; doi:S0171-9335(08)00024-1).
164. Kirkbride K.C., Sung B.H., Sinha S., Weaver A.M. Cortactin: a multifunctional regulator of cellular invasiveness. Cell Adh. Migr. 2011, 5(2). (PMID: 21258212).
165. Van Slambrouck S., Grijelmo C., De Wever O., Bruyneel E., Emami S., Gespach C., Steelant W.F. Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int. J. Oncol. 2007, 31(6):1501-1508. (PMID: 17982677).
166. Kanchanawong P., Shtengel G., Pasapera A.M., Ramko E.B., Davidson M.W., Hess H.F., Waterman C.M. Nanoscale architecture of integrin-based cell adhesions. Nature 2010, 468(7323):580-584. (PMID: 21107430). 10.1038/nature09621.
167. Michael K.E., Dumbauld D.W., Burns K.L., Hanks S.K., Garcia A.J. Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol. Biol. Cell 2009, 20(9):2508-2519. (PMID: 19297531; doi:E08-01-0076).
168. Zhao J., Guan J.-L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009, 28(1-2):35-49. (PMID: 19169797). 10.1007/s10555-008-9165-4.
169. Sincock P.M., Fitter S., Parton R.G., Berndt M.C., Gamble J.R., Ashman L.K. PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J. Cell Sci. 1999, 112(Pt 6):833-844. (PMID: 10036233).
170. Ueda J., Kajita M., Suenaga N., Fujii K., Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003, 22(54):8716-8722. (PMID: 14647466). 10.1038/sj.onc.1206962.
171. Sabeh F., Ota I., Holmbeck K., Birkedal-Hansen H., Soloway P., Balbin M., Lopez-Otin C., Shapiro S., Inada M., Krane S., Allen E., Chung D., Weiss S.J. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 2004, 167(4):769-781. (PMID: 15557125; doi:jcb.200408028).
172. Chen M., O'Toole E.A., Li Y.Y., Woodley D.T. Alpha 2 beta 1 integrin mediates dermal fibroblast attachment to type VII collagen via a 158-amino-acid segment of the NC1 domain. Exp. Cell Res. 1999, 249(2):231-239. (PMID: 10366422). 10.1006/excr.1999.4473.
173. Tandon M., Vemula S.V., Mittal S.K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther. Targets 2011, 15(1):31-51. (PMID: 21142802). 10.1517/14728222.2011.538682.
174. Swart G.W. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur. J. Cell Biol. 2002, 81(6):313-321. (PMID: 12113472).
175. Ofori-Acquah S.F., King J.A. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl. Res. 2008, 151(3):122-128. (PMID: 18279810; doi:S1931-5244(07)00252-6).
176. Breen E., Steele G., Mercurio A.M. Role of the E-cadherin/alpha-catenin complex in modulating cell-cell and cell-matrix adhesive properties of invasive colon carcinoma cells. Ann. Surg. Oncol. 1995, 2(5):378-385. (PMID: 7496831).
177. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 2010, 16(11):2927-2931. (PMID: 20484021). 10.1158/1078-0432.CCR-09-2329.
178. Furusato B., Mohamed A., Uhlén M., Rhim J.S. CXCR4 and cancer. Pathol. Int. 2010, 60(7):497-505. (PMID: 20594270). 10.1111/j.1440-1827.2010.02548.x.
179. Wang J., Loberg R., Taichman R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25(4):573-587. (PMID: 17165132). 10.1007/s10555-006-9019-x.
180. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8(8):579-591. (PMID: 18596824). 10.1038/nrc2403.
181. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 2007, 5(3):203-220. (PMID: 17374728). 10.1158/1541-7786.MCR-06-0404.
182. Malik A., Gerber H. Targeting VEGF ligands and receptors in cancer. Targets 2003, 2(2):48-57. (PMID: 17735688442963322729related:aWfU0avSIfYJ).
183. Fernando H.S., Kynaston H.G., Jiang W.G. WASP and WAVE proteins: vital intrinsic regulators of cell motility and their role in cancer (review). Int. J. Mol. Med. 2009, 23(2):141-148. (PMID: 19148537).
184. Sossey-Alaoui K., Safina A., Li X., Vaughan M.M., Hicks D.G., Bakin A.V., Cowell J.K. Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. Am. J. Pathol. 2007, 170(6):2112-2121. (PMID: 17525277; doi:170/6/2112).
185. Zheng J. Is SATB1 a master regulator in breast cancer growth and metastasis?. Womens Health (Lond. Engl.) 2008, 4(4):329-332. (PMID: 19072498). 10.2217/17455057.4.4.329.